Table 1 Histological data of the MCD mouse model
From: miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice
2 Weeks | 8 Weeks | |||||
|---|---|---|---|---|---|---|
Control | MCD | Control | MCD | |||
WT ( n =5) | WT ( n =10) | miR-21 KO ( n =8) | WT ( n =5) | WT ( n =10) | miR-21 KO ( n =8) | |
Steatosis | ||||||
0 (None) | 80% | 12,5% | 100% | |||
1 (Minimal) | 20% | 10%*** | 12,5% | |||
2 (Mild) | 80% | 50% | 22%*** | 42% | ||
3 (Moderate) | 10% | 25% | 45% | 29% | ||
4 (Severe) | 33% | 29% | ||||
Lobular inflammation | ||||||
0 (None) | 80% | 40% | 25% | 80% | 33%* | 14% |
1 (Mild) | 20% | 50% | 25% | 20% | 11% | 57% |
2 (Moderate) | 50% | 28% | ||||
3 (Severe) | 10% | 56% | ||||
Necrosis | ||||||
0 (None) | 100% | 80% | 33% | 100% | 33%* | 29% |
1 (Mild) | 20% | 67% | 11% | 42% | ||
2 (Moderate) | 29% | |||||
3 (Severe) | 56% | |||||
Pericellular fibrosis | ||||||
0 (None) | 100% | 100% | 100% | 100% | 10%*** | 86%‡ |
1 (Mild) | 80% | 14% | ||||
2 (Moderate) | 10% | |||||
3 (Severe) | ||||||
Hypertrophy | ||||||
0 (None) | 100% | 50% | 62% | 100% | 44%* | 43% |
1 (Mild) | 40% | 43% | ||||
2 (Moderate) | 10% | 38% | 14% | |||
3 (Severe) | 56% | |||||
